- Accueil
- Le département
- Notre équipe
- Pr Andreas Hottinger
Pr Andreas Hottinger
Spécialisations
- Tumeurs primaires du cerveau
- Métastases cérébrales et spinales
- Complications neurologiques du cancer ou de son traitement
Domaines d'intérêt académique et/ou clinique
L’optimisation de la prise en charge des patients souffrant de glioblastomes et de lymphomes cérébraux. Un projet de recherche clinique et fondamentale est en développement pour permettre de mieux évaluer le développement métabolique et les modifications génétiques des tumeurs cérébrales.
Études cliniques sélectionnées en cours
- CL1-49076: Phase I/II study of S 49076, a multitarget inhibitor of c-MET,AXL, FGFr in combination with Bevacizumab in patients with recurrent glioblastoma multiforme
- Checkmate 498: A randomized phase III study of Nivolumab vs Temozolomide in combination with radiation therapy in patients with newly diagnosed GBM and unmethylated MGMT
- XENOGBM: Comparison and validation of high-resolution imaging and molecular profiles of human glioblastoma and respective paired orthotopic xenografts in the mouse^
Publications scientifiques sélectionnées
Initiating or Resuming Cancer Treatment After Ischemic Stroke and Clinical Outcomes.
Costamagna G, Hottinger AF, Strambo D, Livio F, Navi BB, Michel P
Neurology. 2025 Apr 8;104(7):e213458
The value of AI for assessing longitudinal brain metastases treatment response.
Andrearczyk V, Schiappacasse L, Raccaud M, Bourhis J, Prior JO, Cuendet MA, Hottinger AF, Dunet V, Depeursinge A
Neurooncol Adv. 2025 Jan-Dec;7(1):vdae216
Automatic detection and multi-component segmentation of brain metastases in longitudinal MRI.
Andrearczyk V, Schiappacasse L, Abler D, Wodzinski M, Hottinger A, Raccaud M, Bourhis J, Prior JO, Dunet V, Depeurnge A
Sci Rep. 2024 Dec 30;14(1):31603
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
Still MEH, Moor RSF, Ghiaseddin AP, Leibetseder A, Hottinger AF, Berghoff A, Leung D
Neurooncol Pract. 2025 Feb;12(Suppl 1):i19-i25
Cancer Therapy-Induced Encephalitis.
Desbaillets NP, Hottinger AF
Cancers (Basel). 2024 Oct 23;16(21)
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.
Watson SS, Zomer A, Fournier N, Lourenco J, Quadroni M, Chryplewicz A, Nassiri S, Aubel P, Avanthay S, Croci D, Abels E, Broekman MLD, Hanahan D, Huse JT, Daniel RT, Hegi ME, Homicsko K, Cossu G, Hottinger AF, Joyce JA
Cancer Cell. 2024 Sep 9;42(9):1507-1527.e11
Status epilepticus management in patients with brain tumors. A cohort study.
Tziakouri A, Hottinger AF, Novy J, Rossetti AO
Seizure. 2024 Aug;120:1-4
Human stem cell-derived neurons and astrocytes to detect novel auto-reactive IgG response in immune-mediated neurological diseases.
Mathias A, Perriot S, Jones S, Canales M, Bernard-Valnet R, Gimenez M, Torcida N, Oberholster L, Hottinger AF, Zekeridou A, Theaudin M, Pot C, Du Pasquier R
Front Immunol. 2024;15:1419712
Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.
Loser V, Segot A, de Leval L, Bisig B, Brouland JP, Hewer E, Barcena C, Hottinger AF, Pot C
BMC Neurol. 2024 Jul 22;24(1):250
Hypnosis-Assisted Awake Craniotomy for Eloquent Brain Tumors: Advantages and Pitfalls.
Cossu G, Vandenbulcke A, Zaccarini S, Gaudet JG, Hottinger AF, Rimorini N, Potie A, Beaud V, Guerra-Lopez U, Daniel RT, Berna C, Messerer M
Cancers (Basel). 2024 May 5;16(9)
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.
Kinj R, Hottinger AF, Böhlen TT, Ozsahin M, Vallet V, Dunet V, Bouchaab H, Peters S, Tuleasca C, Bourhis J, Schiappacasse L
Cancers (Basel). 2024 Apr 29;16(9)
Acute ischaemic stroke in active cancer versus non-cancer patients: stroke characteristics, mechanisms and clinical outcomes.
Costamagna G, Hottinger AF, Milionis H, Salerno A, Strambo D, Livio F, Navi BB, Michel P
Eur J Neurol. 2024 Apr;31(4):e16200
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M
J Neurol. 2024 Apr;271(4):1947-1958
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment.
Costamagna G, Navi BB, Beyeler M, Hottinger AF, Alberio L, Michel P
Semin Thromb Hemost. 2024 Apr;50(3):342-359
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
Bejarano L, Kauzlaric A, Lamprou E, Lourenco J, Fournier N, Ballabio M, Colotti R, Maas R, Galland S, Massara M, Soukup K, Lilja J, Brouland JP, Hottinger AF, Daniel RT, Hegi ME, Joyce JA
Cancer Cell. 2024 Mar 11;42(3):378-395.e10
[Oncology: what's new in 2023].
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A
Rev Med Suisse. 2024 Jan 17;20(856-7):80-87
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Fischer Maranta A, Läubli H, Hottinger AF, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobagyi T, Held L, Weller M, Wirsching HG
BMC Cancer. 2024 Jan 15;24(1):82
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C, Gramatzki D, Le Rhun E, Hottinger AF, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching HG, Weller M, Roth P
Neurooncol Pract. 2024 Apr;11(2):132-141
The local microenvironment drives activation of neutrophils in human brain tumors.
Maas RR, Soukup K, Fournier N, Massara M, Galland S, Kornete M, Wischnewski V, Lourenco J, Croci D, Álvarez-Prado ÁF, Marie DN, Lilja J, Marcone R, Calvo GF, Santalla Mendez R, Aubel P, Bejarano L, Wirapati P, Ballesteros I, Hidalgo A, Hottinger AF, Brouland JP, Daniel RT, Hegi ME, Joyce JA
Cell. 2023 Oct 12;186(21):4546-4566.e27
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF, INDIGO Trial Investigators
N Engl J Med. 2023 Aug 17;389(7):589-601
Prediction of Glioma Grade and IDH Status Using (18)F-FET PET/CT Dynamic and Multiparametric Texture Analysis.
Hajri R, Nicod-Lalonde M, Hottinger AF, Prior JO, Dunet V
Diagnostics (Basel). 2023 Aug 5;13(15)
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M
Eur J Cancer. 2023 Aug;189:112913
Clinical and Demographic Characteristics, Mechanisms, and Outcomes in Patients With Acute Ischemic Stroke and Newly Diagnosed or Known Active Cancer.
Costamagna G, Hottinger A, Milionis H, Lambrou D, Salerno A, Strambo D, Livio F, Navi BB, Michel P
Neurology. 2023 Jun 13;100(24):e2477-e2489
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.
Wischnewski V, Maas RR, Aruffo PG, Soukup K, Galletti G, Kornete M, Galland S, Fournier N, Lilja J, Wirapati P, Lourenco J, Scarpa A, Daniel RT, Hottinger AF, Brouland JP, Losurdo A, Voulaz E, Alloisio M, Hegi ME, Lugli E, Joyce JA
Nat Cancer. 2023 Jun;4(6):908-924
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A
Invest New Drugs. 2023 Apr;41(2):267-275
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Álvarez-Prado ÁF, Maas RR, Soukup K, Klemm F, Kornete M, Krebs FS, Zoete V, Berezowska S, Brouland JP, Hottinger AF, Daniel RT, Hegi ME, Joyce JA
Cell Rep Med. 2023 Jan 17;4(1):100900
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Rudà R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC
Neuro Oncol. 2023 Jan 5;25(1):37-53
[Management of brain metastases in 2022].
Schiappacasse L, Kinj R, De Micheli R, Mederos N, Tuleasca C, Cossu G, Dunet V, Levivier M, Bourhis J, Hottinger AF
Rev Med Suisse. 2022 May 18;18(782):976-983
Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of methe Phase 3 EF-14 Clinical Trial.
Ram Z, Kim CY, Hottinger AF, Idbaih A, Nicholas G, Zhu JJ
Front Oncol. 2022;12:902929
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M, Ballo MT, Bomzon Z, Urman N, Levi S, Lavy-Shahaf G, Jeyapalan S, Sio TT, DeRose PM, Misch M, Taillibert S, Ram Z, Hottinger AF, Easaw J, Kim CY, Mohan S, Stupp R
Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1269-1278
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol. 2022 Feb 1;40(4):403-426
[Neurology : what's new in 2021].
Vicino A, Allali G, Bally J, Castro Jimenez M, Chiabotti Salvioni P, Hirt L, Hottinger A, Michel P, Novy J, Pot Kreis C, Rossetti A, Rouaud O, Ryvlin P, Théaudin M, Du Pasquier R
Rev Med Suisse. 2022 Jan 19;18(764-5):51-55
MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D, Barritault M, Montané L, Laigle-Donadey F, Chinot O, Le Rhun E, Bonneville-Levard A, Hottinger AF, Meyronnet D, Bidaux AS, Garin G, Pérol D
Neuro Oncol. 2021 Nov 2;23(11):1949-1960
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z, Kim CY, Hottinger AF, Idbaih A, Nicholas G, Zhu JJ
Front Oncol. 2021;11:671972
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.
Cudalbu C, Bady P, Lai M, Xin L, Gusyatiner O, Hamou MF, Lepore M, Brouland JP, Daniel RT, Hottinger AF, Hegi ME
Acta Neuropathol Commun. 2021 Aug 4;9(1):133
Slowness Predicts Mortality: A Comparative Analysis of Walking Speed and Moberg Picking-Up Tests.
Meyer ML, Fustinoni S, Henchoz Y, Hottinger AF, Santos-Eggimann B
J Am Med Dir Assoc. 2021 Aug;22(8):1652-1657.e2
Immunotherapy in Glioblastoma: A Clinical Perspective.
Desbaillets N, Hottinger AF
Cancers (Basel). 2021 Jul 24;13(15)
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM).
Hofer S, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Pflugshaupt T, Eggenberger N, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching HG, Wolpert F, Roth P, Weller M
Swiss Med Wkly. 2021 May 10;151:w20501
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M
Front Oncol. 2021;11:679702
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, Tzuk-Shina T, Lucas A, Freixa SV, Golfinopoulos V, Gorlia T, Hottinger AF, Stupp R, Baumert BG
Neuro Oncol. 2021 May 5;23(5):803-811
[Recent Advances in Neurology].
Anichini A, Salvioni Chiabotti P, Bally J, Castro Jimenez M, Démonet JF, Di Virgilio G, Hirt L, Hottinger A, Kuntzer T, Michel P, Novy J, Pot Kreis C, Rossetti AO, Rouaud O, Théaudin M, Du Pasquier R
Rev Med Suisse. 2021 Jan 27;17(723):196-200
MRI and (18)FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.
Wirsching HG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, von Moos R, Caparrotti F, Conen K, Remonda L, Roth P, Ochsenbein A, Tabatabai G, Weller M
Clin Cancer Res. 2021 Jan 1;27(1):179-188
Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.
Daccord C, Nicolas A, Demicheli R, Chehade H, Hottinger AF, Beigelman C, Lazor R
Respir Med Case Rep. 2020;31:101310
Physical approaches to treat glioblastoma.
Latifyan S, de Micheli R, Hottinger AF
Curr Opin Oncol. 2020 Nov;32(6):640-649
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A, Hottinger A, Wolf B, Navarro Rodrigo B, Ochoa de Olza M, Auger A, Kuntzer T, Comte D, Zimmer V, Gannon P, Kandalaft L, Michielin O, Zimmermann S, Harari A, Trueb L, Coukos G
J Immunother Cancer. 2020 Aug;8(2)
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Roth P, Hottinger AF, Hundsberger T, Läubli H, Schucht P, Reinert M, Mamot C, Roelcke U, Pesce G, Hofer S, Weller M
Swiss Med Wkly. 2020 Jun 1;150:w20256
Glioma patient-reported outcome assessment in clinical care.
Tuleasca C, Knisely J, Leroy HA, Hottinger AF, Peciu-Florianu I, Levivier M, Reyns N
Lancet Oncol. 2020 May;21(5):e230
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
Mohile NA, Blakeley JO, Gatson NTN, Hottinger AF, Lassman AB, Ney DE, Olar A, Schiff D, Shih HA, Strowd R, van den Bent MJ, Ziu M
Neuro Oncol. 2020 Apr 11;22(7):912-7
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Panje CM, Putora PM, Hundsberger T, Hottinger AF, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K
Swiss Med Wkly. 2019 Dec 2;149:w20153
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V
J Immunother Cancer. 2019 Dec 2;7(1):336
Recent developments and controversies in primary central nervous system lymphoma.
Hottinger AF, Alentorn A, Hoang-Xuan K
Curr Opin Oncol. 2015 Nov;27(6):496-501
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M, European Association
Lancet Oncol. 2015 Jul;16(7):e322-32
Education et formation
Spécialiste en oncologie médicale, membre FMH: 2011
Spécialiste en neurologie, membre FMH: 2008
Thèse (neurodégénération): 2001
Diplôme de médecine: 1995
Institutions de formation & expériences précédentes
Université de Lausanne
- Hôpitaux Universitaires de Genève
- Memorial Sloan Kettering Cancer Center (New York)
- Inselspital (Berne)
Langues parlées
Français, Allemand, Anglais
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155